The Clinical Study Plan on Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan for Bullous Keratopathy Patient approved by MHLW‘s Health Science Council
Tokyo (July 2, 2021)-, Japanese Ministry of Health and Labor, and Welfare conditionally approved the first in human clinical research plan to transplant corneal endothelial cell substitute from iPS cells into Bullous Keratopathy patients. The research will be leaded by Prof. Shigeto Shimmura’s team, the collaborator of Cellusion, in Keio University. The study will start in Keio University hospital after document correction pointed out by MHLW and obtaining official approval.
Parallel to this clinical study, Cellusion is preparing for starting P1/2 clinical trial in Japan. With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.
<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/